P. Valent, C. Akin, and L. Escribano, Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria, Eur J Clin Invest, vol.37, pp.435-53, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00152499

P. Valent, H. P. Horny, and L. Escribano, Diagnostic criteria and classification of mastocytosis: a consensus proposal, Leuk Res, vol.25, pp.603-628, 2001.

F. Lanternier, A. Cohen-akenine, and F. Palmerini, Phenotypic and genotypic characteristics of mastocytosis according to the age of onset, PLoS ONE, vol.3, p.1906, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00282484

C. Bodemer, O. Hermine, and F. Palmérini, Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations, J Invest Dermatol, vol.130, pp.804-819, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00437282

L. Escribano, B. Díaz-agustín, and C. Bellas, Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis, Leuk Res, vol.25, pp.563-70, 2001.

L. Escribano, B. Diaz-agustin, and A. López, Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish network on mastocytosis (REMA), Cytometry B Clin Cytom, vol.58, pp.1-8, 2004.

C. Teodosio, A. C. García-montero, and M. Jara-acevedo, Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes, J Allergy Clin Immunol, vol.125, pp.1-726, 2010.

S. Georgin-lavialle, L. Lhermitte, and C. Baude, Blood CD34-c-Kit? cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor, Blood, vol.118, pp.5246-5255, 2011.

M. J. Frost, P. T. Ferrao, and T. P. Hughes, Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant, Mol Cancer Ther, vol.1, pp.1115-1139, 2002.

H. Bougherara, F. Subra, and R. Crépin, The aberrant localization of oncogenic Kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment, Mol Cancer Res, vol.7, pp.1525-1558, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00421163

P. Valent, H. P. Horny, L. Escribano, and B. J. Longley, Mastocytosis (mast cell disease). World Health Organization (WHO) Classification of Tumours, vol.1, pp.291-302, 2001.

L. Escribano, A. Orfao, and B. Dìaz-augustìn, Indolent Systemic Mast Cell Disease in Adults: Immunophenotypic Characterization of Bone Marrow Mast Cells and its Diagnostic Implications, Blood, vol.98, pp.2731-2737, 1998.

S. Verstovsek, A. Tefferi, and J. Cortes, Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis, Clin Cancer Res, vol.14, pp.3906-3921, 2008.

C. Ustun, C. L. Corless, and N. Savage, Chemotherapy and dasatinib induce longterm hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT, Leuk Res, vol.816, pp.735-776, 2009.

A. Hochhaus, H. M. Kantarjian, and M. Baccarani, Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy, Blood, vol.109, pp.2303-2312, 2007.

J. Gotlib, C. Bérubé, and J. D. Growney, Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation, Blood, vol.106, pp.2865-70, 2005.

S. Tabone-eglinger, F. Subra, E. Sayadi, and H. , KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors, Clin Cancer Res, vol.14, pp.2285-94, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00283136

C. Choudhary, J. V. Olsen, and C. Brandts, Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes, Mol Cell, vol.36, pp.326-365, 2009.

P. Mazot, A. Cazes, and M. C. Boutterin, The constitutive activity of the ALK mutated at positions F1174 or R 1275 Impairs receptor trafficking, Oncogene, vol.30, pp.2017-2042, 2011.